PDCD1 and metastatic melanoma: Toripalimab is a recombinant, humanized IgG4 monoclonal PD-1 antibody that was developed by Shanghai Junshi Bioscience Co., Ltd. (Junshi Bio) and was first approved for the treatment of unresectable or metastatic melanoma in China on December 17, 2018.